The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Metabolic Syndrome: Focus on Dyslipidemia
Abstract
In 2001, the National Cholesterol Education Program Adult Treatment Panel III guidelines defined a cluster of metabolic factors that increase the risk for atherosclerotic cardiovascular disease (ASCVD)1 (1). They called this cluster the "metabolic syndrome" and defined afflicted individuals by the presence of three of the following five characteristics: central obesity, hypertriglyceridemia, low high-density lipoprotein (HDL)-cholesterol levels, hypertension, and either impaired fasting glucose or type 2 diabetes (Table 1). An analysis of data from 8814 men and women in the Third National Health and Nutrition Examination Survey (1988 to 1994) that used the Adult Treatment Panel III definition of the metabolic syndrome indicates that the age-adjusted prevalence of the syndrome was 23.7% in the U.S. population ≥20 years of age (2). A recent update of National Health and Nutrition Examination Survey data (3) indicates increases in the prevalence of the metabolic syndrome in all age and both sex groups. Although Reaven (4) popularized the concept of the clustering of insulin resistance, a dyslipidemia characterized by hypertriglyceridemia, low HDL-cholesterol, and hypertension, in his Banting Lecture of 1988, the initial observations of associations between components of the metabolic syndrome were published much earlier by Vague (5), Albrink and Meigs (6), and Reaven et al. (7). Furthermore, the World Health Organization defined a slightly different version of the metabolic syndrome in 1998 (8). However, the formal presentation of the metabolic syndrome by the Adult Treatment Panel III panel has made the metabolic syndrome into a major topic for medical discussion. The contribution of the metabolic syndrome to atherosclerotic disease can be illustrated, at least in part, by the more extensively examined relationship of diabetes to atherosclerotic disease. Atherosclerosis accounts for ∼80% of all diabetic mortality (9), with 75% attributed to coronary atherosclerosis and 25% to cerebral or peripheral vascular disease. Atherosclerosis also accounts for >75% of all hospitalizations for diabetic complications. It has been estimated that >50% of patients with newly diagnosed type 2 diabetes have coronary heart disease (CHD). Among 350, 977 non-diabetic and 5245 diabetic subjects screened for enrollment in the Multiple Risk Factor Intervention Trial (10), the risk of ASCVD mortality in both groups increased with an increasing number of classical risk factors, but ASCVD mortality was significantly increased in the diabetics at all levels of risk. In a study by Haffner et al. (11), the 7-year incidence rates of myocardial infarction (MI) among 1373 patients without diabetes were 3.5% in those without prior MI and 18.8% in those with prior MI. Among the 1059 diabetic patients, the MI rate in those without prior MI was 20.2% (comparable with that in non-diabetic patients with prior MI), whereas the rate was 45% in patients with prior MI. Data such as these led the Adult Treatment Panel III to designate diabetes as a CHD equivalent. Although ∼80% to 90% of individuals with type 2 diabetes meet the criteria of the metabolic syndrome, it is important to look carefully at the risk for ASCVD in the group with metabolic syndrome but without diabetes. Epidemiological data indicate that impaired glucose tolerance increases risk for ASCVD mortality. In the 10-year Paris Prospective Study follow-up of >7000 men (12), CHD mortality rates were significantly increased by ∼2-fold in subjects with impaired glucose tolerance or with diabetes newly diagnosed on the basis of glucose tolerance testing. In the Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe study group analysis (13) of data from 10 European studies involving more than 22, 000 participants (15, 388 men and 7126 women) followed for a median of 8.8 years, impaired glucose tolerance was associated with multivariate-adjusted hazard ratios of 1.28 (95% CI, 1.02 to 1.59) for CHD death, 1.34 (95% CI, 1.14 to 1.57) for cardiovascular death, and 1.40 (95% CI, 1.27 to 1.54) for all-cause mortality. In an analysis of 3174 subjects in the U.S. Second National Health and Nutrition Examination Survey Mortality Study who underwent oral glucose tolerance testing and were followed from 1976–1980 through 1992 (14), impaired glucose tolerance was associated with multivariate-adjusted relative risks of 1.42 (95% CI, 1.08 to 1.87) for all-cause mortality and 1.15 (95% CI, 0.81 to 1.62) for cardiovascular mortality. All of these studies, however, predated the Adult Treatment Panel III publication defining the metabolic syndrome. A number of recent studies have used the definition of the metabolic syndrome by either Adult Treatment Panel III or the World Health Organization to determine the impact of this syndrome on ASCVD or CHD. Isomaa et al. (15) assessed cardiovascular morbidity and mortality associated with the World Health Organization metabolic syndrome (defi
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234
Obesity-induced inflammatory changes in adipose tissue
Wellen, K. E., & Hotamisligil, G. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320514 · Cited by 1,823
Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
Cited by
Association between insulin resistance and the development of cardiovascular disease
Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., & Zuñiga, F. A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0762-4 · Cited by 2,280
Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus
Tangvarasittichai, S. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.456 · Cited by 1,213
Identification of a Lipokine, a Lipid Hormone Linking Adipose Tissue to Systemic Metabolism
Cao, H., Gerhold, K., Mayers, J. R., Wiest, M. M., Watkins, S. M., & Hotamisligil, G. S. (2008) · Cell · doi:10.1016/j.cell.2008.07.048 · Cited by 1,139
Regulation of Hepatic Lipogenesis by the Transcription Factor XBP1
Lee, A.-H., Scapa, E. F., Cohen, D. E., & Glimcher, L. H. (2008) · Science · doi:10.1126/science.1158042 · Cited by 977
Bile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H.-U. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 532
Biddinger, S. B., Hernandez-Ono, A., Rask-Madsen, C., Haas, J. T., Alemán, J. O., Suzuki, R., Scapa, E. F., Agarwal, C., Carey, M. C., Stephanopoulos, G., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.013 · Cited by 469
Self-citationQuehenberger, O., & Dennis, E. A. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1104901 · Cited by 454
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
Resolving the paradox of hepatic insulin resistance
Santoleri, D., & Titchenell, P. M. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.10.016 · Cited by 336
Bile Acid Metabolism and Signaling
Chiang, J. Y. L. (2013) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2013.tb00517.x · Cited by 279
Brain Insulin Controls Adipose Tissue Lipolysis and Lipogenesis
Scherer, T., O'Hare, J., Diggs-Andrews, K., Schweiger, M., Cheng, B., Lindtner, C., Zielinski, E., Vempati, P., Su, K., Dighe, S., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.01.008 · Cited by 262
Franssen, R., Monajemi, H., Stroes, E. S. G., & Kastelein, J. J. P. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.003 · Cited by 270
Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.044 · Cited by 243
Understanding bile acid signaling in diabetes: From pathophysiology to therapeutic targets
Ferrell, J. M., & Chiang, J. Y. L. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0043 · Cited by 139
Chan, D. C., & Watts, G. F. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.502529 · Cited by 69
Metadata
- Authors
- Ginsberg, H. N., Zhang, Y., & Hernandez‐Ono, A.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2006-02
- Volume
- 14
- Issue
- S2
- Pages
- 41S-49S
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2054239245
- Cited by
- 228
- References
- 15
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.